ATAIBECKLEY INC

El Lilly completes $3.8 bn acquisition of AtaiBeckley, boosting its neuroscience pipeline for depression and other mental‑health disorders.

Learn how Eli Lilly’s $3.8 billion purchase of AtaiBeckley marks a bold move into psychedelic medicine, boosting its portfolio and future growth.

ATAI Life Sciences NV’s AtaiBeckley Inc. plans a $5.17‑share sale of 100,000 shares by a director, revealing key financial strategy and compliance for investors.

AtaiBeckley completes Phase 2b dosing of psychedelic VLS‑01, eyeing a Phase 3 MDD trial in 2027 and sparking takeover interest.

ATAIBECKLEY INC advances rapid‑acting mental‑health drugs for depression and anxiety, eyeing Phase II breakthroughs that could lift its stock beyond $6.75.

AtaiBeckley joins the Russell 2000 & 3000, boosting U.S. visibility & liquidity as it advances psychedelic & non‑psychedelic mental‑health therapies.

AtaiBeckley surges 28% after Trump’s FDA fast‑track order for psychedelic therapies—analyst upgrades and a new regulatory path could unlock big upside for investors.

AtaiBeckley explores $2B+ deals for its psychedelic nasal spray BPL‑003, seeking a sale, co‑commercial or royalty partnership to accelerate its depression therapy launch.

AtaiBeckley’s FDA‑backed Phase 3 launch of the intranasal rapid‑acting antidepressant BPL‑003 could transform treatment‑resistant depression, offering quick, durable relief.

AtaiBeckley Inc. shares fall to $3.75 as the Nasdaq‑listed mental‑health biotech, linked to Berlin’s ATAI Life Sciences, projects 2026 growth amid a P/E of –4.88, a 5.98 P/B and a $1.36 bn market cap.